The work of Dr. Hans Nieper
Hans A. Nieper, MD (1928-1998) was a well-known internist from Hanover, Germany who developed unique biological approaches to the treatment of cancer and multiple sclerosis, as well as other diseases.
The specialized medical developments that Dr. Nieper is known for include – the unique transporting capabilities of mineral carriers such as the aspartates and orotates; treatment of MS with calcium EAP; normalization of Pap test stages with squalene and vitamin C; cancer therapy utilizing the deshielding properties of bromelain and the use of gene repair substances; and cardiovascular treatment with serrapeptidase and the orotate and aspartate forms of several minerals.
The formation of arterial plaque involves deposits of fatty substances, cholesterol, cellular waste products, calcium and fibrin (a clotting material in the blood) on the inner lining of the arteries. Excessive plaque results in partial or complete blockage of the blood's flow through an artery, resulting in arteriosclerosis, and potentially a stroke or heart attack.
Dr. Nieper studied the effects of serrapeptidase on plaque accumulations in the arteries, and began using ultrasound to examine the arteries of his patients. He found that within 12 to 18 months of serrapeptidase treatment (combined with magnesium oratate, bromelain, L-carnitine, vitamin B1, and selenium), blockages in hardened arteries were often significantly reduced.
He stated: “In cases of severe arterial narrowing, I have used serrapeptidase with excellent, even life-saving results. Many of my patients have shown significantly improved blood flow through their previously constricted arteries, as confirmed by ultrasound examination. Serrapeptidase is extremely useful in keeping arterial deposits from building up again after angioplasty or coronary bypass surgery has been performed.”
Dr. Nieper called serrapeptidase “the miracle enzyme”. His files included many cases of patients who were able to experience restored circulation and mobility. However, this evidence is still anecdotal. Further studies are called for in this area as Nieper's research indicated that the protein-dissolving action of serrapeptidase gradually breaks down atherosclerotic plaques.